Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 216.48
ATHX's Cash to Debt is ranked higher than
80% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. ATHX: 216.48 )
ATHX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 216.48

Equity to Asset 0.75
ATHX's Equity to Asset is ranked higher than
80% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ATHX: 0.75 )
ATHX' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.93
Current: 0.75

0.19
0.93
F-Score: 4
Z-Score: -4.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -990.63
ATHX's Operating margin (%) is ranked higher than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. ATHX: -990.63 )
ATHX' s 10-Year Operating margin (%) Range
Min: -1616.36   Max: -128.77
Current: -990.63

-1616.36
-128.77
Net-margin (%) -994.61
ATHX's Net-margin (%) is ranked higher than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. ATHX: -994.61 )
ATHX' s 10-Year Net-margin (%) Range
Min: -1540.94   Max: -127.27
Current: -994.61

-1540.94
-127.27
ROE (%) -126.51
ATHX's ROE (%) is ranked higher than
56% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. ATHX: -126.51 )
ATHX' s 10-Year ROE (%) Range
Min: -1459900   Max: -45.44
Current: -126.51

-1459900
-45.44
ROA (%) -79.93
ATHX's ROA (%) is ranked higher than
56% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. ATHX: -79.93 )
ATHX' s 10-Year ROA (%) Range
Min: -1459900   Max: -41.79
Current: -79.93

-1459900
-41.79
ROC (Joel Greenblatt) (%) -1910.52
ATHX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. ATHX: -1910.52 )
ATHX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1397000   Max: -1240.32
Current: -1910.52

-1397000
-1240.32
Revenue Growth (%) -56.00
ATHX's Revenue Growth (%) is ranked higher than
57% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ATHX: -56.00 )
ATHX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 41.2
Current: -56

0
41.2
EBITDA Growth (%) -10.70
ATHX's EBITDA Growth (%) is ranked higher than
74% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ATHX: -10.70 )
ATHX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -10.7
Current: -10.7

EPS Growth (%) -4.10
ATHX's EPS Growth (%) is ranked higher than
80% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. ATHX: -4.10 )
ATHX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -4.1
Current: -4.1

» ATHX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ATHX Guru Trades in Q3 2013

Jean-Marie Eveillard 4,207,600 sh (unchged)
Jim Simons 11,467 sh (-97.1%)
» More
Q4 2013

ATHX Guru Trades in Q4 2013

Jim Simons 345,845 sh (+2916%)
Jean-Marie Eveillard 4,207,600 sh (unchged)
» More
Q1 2014

ATHX Guru Trades in Q1 2014

Chuck Royce 929,000 sh (New)
George Soros 157,000 sh (New)
Jean-Marie Eveillard 2,985,414 sh (-29.05%)
Jim Simons 30,500 sh (-91.18%)
» More
Q2 2014

ATHX Guru Trades in Q2 2014

Jean-Marie Eveillard 3,585,414 sh (+20.1%)
Jim Simons Sold Out
George Soros Sold Out
Chuck Royce 865,000 sh (-6.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$1.33 - $3.39 $ 1.39-29%0
Jean-Marie Eveillard 2014-06-30 Add 20.1%$1.33 - $3.39 $ 1.39-29%3585414
George Soros 2014-03-31 New Buy0.01%$2.43 - $4.18 $ 1.39-62%157000
Jean-Marie Eveillard 2014-03-31 Reduce -29.05%0.01%$2.43 - $4.18 $ 1.39-62%2985414
Jean-Marie Eveillard 2012-12-31 Add 1002.63%0.01%$0.95 - $1.33 $ 1.3930%4207600
Jean-Marie Eveillard 2012-09-30 Add 537.05%$1.39 - $1.64 $ 1.39-9%381598
Jean-Marie Eveillard 2012-06-30 New Buy$1.28 - $1.65 $ 1.39-3%59901
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
ATHX's P/B is ranked higher than
81% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. ATHX: 3.70 )
ATHX' s 10-Year P/B Range
Min: 0.18   Max: 25.25
Current: 3.7

0.18
25.25
P/S 38.70
ATHX's P/S is ranked lower than
52% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. ATHX: 38.70 )
ATHX' s 10-Year P/S Range
Min: 1.16   Max: 101.5
Current: 38.7

1.16
101.5
EV-to-EBIT -2.72
ATHX's EV-to-EBIT is ranked lower than
52% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ATHX: -2.72 )
ATHX' s 10-Year EV-to-EBIT Range
Min: -9.3   Max: 3
Current: -2.72

-9.3
3
Current Ratio 8.85
ATHX's Current Ratio is ranked higher than
88% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ATHX: 8.85 )
ATHX' s 10-Year Current Ratio Range
Min: 0.47   Max: 12.58
Current: 8.85

0.47
12.58
Quick Ratio 8.85
ATHX's Quick Ratio is ranked higher than
88% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. ATHX: 8.85 )
ATHX' s 10-Year Quick Ratio Range
Min: 0.47   Max: 12.58
Current: 8.85

0.47
12.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.78
ATHX's Price/Net Cash is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 109.33 vs. ATHX: 3.78 )
ATHX' s 10-Year Price/Net Cash Range
Min: 0.33   Max: 23
Current: 3.78

0.33
23
Price/Net Current Asset Value 3.69
ATHX's Price/Net Current Asset Value is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 50.05 vs. ATHX: 3.69 )
ATHX' s 10-Year Price/Net Current Asset Value Range
Min: 0.33   Max: 17.89
Current: 3.69

0.33
17.89
Price/Tangible Book 3.50
ATHX's Price/Tangible Book is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9.08 vs. ATHX: 3.50 )
ATHX' s 10-Year Price/Tangible Book Range
Min: 0.27   Max: 23.17
Current: 3.5

0.27
23.17
Earnings Yield (Greenblatt) -34.80
ATHX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ATHX: -34.80 )
ATHX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 32.8   Max: 17247.5
Current: -34.8

32.8
17247.5
Forward Rate of Return (Yacktman) -47.66
ATHX's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ATHX: -47.66 )
ATHX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1376.9   Max: -29.4
Current: -47.66

-1376.9
-29.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4LS.Germany
Athersys, Inc. was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The company's current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Potential applications of MultiStem include the treatment of cardiovascular disease, cancer treatment related transplant support, certain neurological conditions, autoimmune disease and other conditions. Factors expressed by MultiStem are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing in other ways. In its current Phase I clinical trial, it is exploring the use of MultiStem as a treatment for damage caused by myocardial infarction, or heart attack. Myocardial infarction is one of the causes of death and disability in the United States. In addition, the Company is developing pharmaceuticals including MultiStem AMI; MultiStem Stroke; and H3 Antagonist cognition to enhance wakefulness and cognitive abilities in individuals suffering from Narcolepsy or Excessive Daytime Sleepiness.
» More Articles for ATHX

Headlines

Articles On GuruFocus.com
comment on ATHX Mar 02 2013 
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Other Websites
Athersys to Host Third Quarter 2014 Financial Results Call Oct 17 2014
Athersys to Host Third Quarter 2014 Financial Results Call Oct 17 2014
Athersys to Present at 2014 Stem Cell Meeting on the Mesa Sep 29 2014
5 Breakout Stocks Under $10 Set to Soar Higher Sep 18 2014
ATHERSYS, INC / NEW Financials Aug 19 2014
Athersys Loss In Line with Expectations, Revenues Down Y/Y Aug 13 2014
Intercept Pharma Soars On Positive Liver Drug Data Aug 11 2014
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 11 2014
Athersys Reports Second Quarter 2014 Results Aug 11 2014
Q2 2014 Athersys, Inc. Earnings Release - After Market Close Aug 11 2014
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies Jul 30 2014
ATHERSYS, INC / NEW Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2014
Wall Street Remaining Bullish on Athersys After Interim Data on UC Trial Jun 16 2014
Athersys: Down But Not Out - An Interview With CEO Van Bokkelen May 22 2014
Athersys Reports Wider-than-Expected Q1 Loss May 14 2014
Athersys' (ATHX) CEO Gil Van Bokkelen on Q1 2014 Results - Earnings Call Transcript May 12 2014
Athersys reports Q1 adjusted EPS (9c), consensus (10c) May 08 2014
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
Athersys (ATHX) in Focus: Stock Slumps 51.3% Apr 29 2014
Why Athersys (ATHX) Stock Plummeted to a One-Year Low Today Apr 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK